Khiron Life Sciences Corp. (TSXV:KHRN) was recently featured on a PotNetwork exclusive article in light of the company’s debut on the TSX-V.

Describing the progress the company has made so far, CEO Alvaro Torres said, “I can assure you, if you go to Colombia today and ask about medical cannabis, the first name that will come up in everybody’s words and minds is Khiron.” Khiron is Colombia’s first company outside of the mining industry to go public on the Toronto Stock exchange.


Torres believes that Khiron is paving the path for new Colombian entrepreneurs and venture capitalists by proving that there are other ways to raise capital in more efficient capital markets. Describing this as a significant milestone for the company, Torres believes that the company is a unique entity in the cannabis industry being a Canadian company with operations in Colombia. The company’s goal at the moment is to cater to Colombia’s emerging Cannabis industry by “winning the hearts and minds of both doctors and patients across the country.” Their goal is to “normalize medical cannabis as much as possible, to make both doctors and patients feel comfortable.”

Furthermore, the article briefly touches upon the company’s next move, which would be to expand across all of Latin America. “We’re looking now to enter into Mexico,” Torres noted. “We believe that, now that the government of Colombia has done all of this regulation, every county in the region is following suit.”

To read the full article, click here.

Click here to connect with Khiron Life Sciences Corp. (TSXV:KHRN) for an Investor Presentation

Source: www.potnetwork.com

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less

Achievements with Scalability and Compatibility Pave Way for Next Phase of Advancement

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s holding, Arcology, a cluster-computing powered AI blockchain ecosystem with unlimited scalability, has updated its working roadmap in response to its Testnet 1.0 results

Keep reading... Show less